Q-omics provides the consensus-scored C11orf96 profile across patient tissues and cancer cell-line models. C11orf96 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, C11orf96 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, C11orf96 protein abundance shows 26,087 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KICH, and LSCC as cancer lineages where C11orf96 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C11orf96 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C11orf96 survival associations across molecular data types. C11orf96 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C11orf96 RNA expression–survival associations across cancer types. High C11orf96 expression shows unfavorable associations in KIRP, LUSC, THCA, HNSC and MESO, but favorable associations in UVM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for C11orf96 RNA expression.
This table summarizes C11orf96 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C11orf96. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C11orf96 shows lower tumor expression in KICH, BLCA, KIRP, LUAD, UCEC and LUSC. The KICH box plot shows higher C11orf96 RNA expression in normal versus tumor tissue (log2 FC = −3.637, t-test p < 0.001).
This table shows molecular features associated with C11orf96 in patient tissues and cancer cell lines. In patient samples, C11orf96 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, C11orf96 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
